KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development.

In this webinar, hosted by DDW, researchers from Champions Oncology will present findings from a 50+ model KRAS-mutant patient-derived xenograft (PDX) cohort spanning non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. Drawing on multi-omic characterisation and integrated genomic analysis, they will explore how KRAS allele type, co-driver mutations, and prior treatment history shape tumour response to pan-RAS(ON) inhibition.

The session will cover intrinsic sensitivity patterns across indications, differential gene expression signatures that distinguish responders from non-responders, and longitudinal data capturing how acquired resistance develops under continuous treatment pressure. Together, these findings illustrate how deeply annotated PDX platforms can define the molecular determinants of RAS inhibitor response and inform rational combination strategies.

This webinar is designed for preclinical and translational leaders in the pharmaceutical and biotech industries working in the KRAS space who want a grounded, data-driven perspective on where the field is heading and how patient-derived platforms are shaping drug development decisions.

A live Q&A with the speakers follows the presentations.

Register now!

 

Supported by